InterPharmaLink

What InterPharmaLink does

InterPharmaLink AG is a privately-held, Basel-based transaction and business advisory firm serving global healthcare companies, service providers, and investors. Founded in 2003, the firm operates across four integrated service lines: M&A Partnering (transaction advisory and due diligence), Enterprise and Production Development (growth strategy and manufacturing footprint optimization), Operational Improvement (supply chain and launch readiness), and Quality and Sustainability (quality systems and regulatory compliance). The firm is built on a senior-executive bench with deep operational pedigrees at Novartis, Sandoz, CSL Behring, and other major pharmaceutical companies, augmented by senior advisors including former regulators from the US FDA, Swissmedic, and AGES.

The firm's revenue model is professional services advisory fees generated through one-time mandates tied to M&A, licensing, due diligence, and strategic consulting engagements, with pricing structured per engagement rather than through productized offerings. Go-to-market is enterprise field sales driven by personal relationships and reputation rather than broad marketing, with a single LinkedIn page as the primary external communication channel. Distribution is direct advisory engagement with senior executives at target companies, supported by a strategic alliance with Conscious Performance GmbH for post-merger integration and organizational effectiveness work.

Customer segments span global pharmaceutical, biotech, generics, biosimilars, and cell and gene therapy companies, alongside healthcare-focused private equity and investment firms (Bain Capital, KKR, CVC, Permira, Warburg Pincus, Advent International, Goldman Sachs). The firm has a 20+ year transaction history spanning both modest licensing deals and large transformational M&A, including CSL's $11.7bn acquisition of Vifor Pharma (2021) and the $960m sale of Arvelle Therapeutics to Angelini Pharma (2021). No public revenue, headcount, or valuation disclosures are available, and the firm operates as a partner-owned boutique without external equity sponsorship.

Name

InterPharmaLink

Legal name

InterPharmaLink AG

Website

https://interpharmalink.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

InterPharmaLink is a Basel-based transaction and business advisory firm serving global pharmaceutical, biotech, generics, and healthcare PE clients with M&A, licensing, operational, and quality advisory services delivered by senior ex-pharma executives.

Ownership category

akta.pro rank

Product category

Healthcare Transaction Advisory

NAICS

Other Management Consulting Services (541618), Professional, Scientific, and Technical Services (54)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

M&A Advisory (Buy-side/Sell-side) (BPAHADAC)

akta.pro secondary industry

Corporate Development & Strategic Partnerships Advisory (JVs, Alliances, Carve-outs) (BPAHAOAG)

Keywords

• Pharmaceutical M&A advisory
• Healthcare transaction advisory
• Due diligence consulting
• Operational improvement advisory
• Quality systems consulting

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Transaction and Business Advisory: Advisory fees for M&A transactions, due diligence services, and strategic consulting engagements. Revenue generated through professional services engagements typically structured as one-time advisory mandates with fees based on transaction complexity and scope.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

InterPharmaLink is a transaction and business advisory firm serving global healthcare companies, service providers, and investors. The firm delivers end-to-end advisory across four competency areas: M&A Partnering (buy/sell-side advisory, due diligence, licensing/partnering), Enterprise and Production Development (growth strategies, geographical expansion, manufacturing strategy), Operational Improvement (supply chain, network optimization, technical development), and Quality and Sustainability (QMS, compliance, regulatory inspection preparation).

Product overview

InterPharmaLink is a transaction and business advisory firm for global healthcare companies, service providers and investors, staffed by a seasoned team of senior industry executives. The company offers four integrated service offerings: M&A Partnering (end-to-end transaction advisory and due diligence), Enterprise and Production Development (strategic advisory for growth and geographical expansion), Operational Improvement (hands-on implementation for supply chain and manufacturing optimization), and Quality and Sustainability (quality systems and regulatory compliance advisory). These services work together to support clients along the value chain from Development through Manufacturing and Supply to Commercial.

Differentiator

Problem solved

Functional benefit

Products and services

• M&A Partnering

Quantifiable outcome

• Successful sale of Selcia to Eurofins in January 2018
• +3 more outcomes

Named customers26 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Conscious Performance GmbHcoreStrategic or Co-development PartnerStrategic alliance bringing together InterPharmaLink's healthcare strategy, transactions, and operational advisory expertise with Conscious Performance's science-based approach to organizational effectiveness and human performance. The partnership addresses the human dimension of strategic transformation including M&A, post-merger integration, joint ventures, and large-scale organizational change where both strategic execution and cultural alignment are critical to success.

Scale indicators2 records

Recent moves5 records

Expansion highlights10 records

Direct peers

• Trinity Partners: US-based healthcare-focused strategy consulting firm serving pharma, biotech, and medical device clients with commercial and transaction advisory. Directly comparable boutique peer to InterPharmaLink in specialist healthcare advisory.
• ZS Associates: Global consulting firm with a deep pharma and biotech practice covering strategy, M&A, commercial, and operational work for healthcare clients. Comparable to InterPharmaLink in serving major pharma manufacturers and healthcare investors with specialist advisory services.
• Simon-Kucher & Partners: Global consulting firm with a strong healthcare and life sciences practice focused on commercial strategy, pricing, and transaction support. Comparable to InterPharmaLink in serving pharma and biotech clients with specialist advisory engagements, including M&A support.
• LEK Consulting: London-headquartered strategy consulting firm with one of the most established dedicated healthcare and life sciences practices globally. Directly comparable to InterPharmaLink in serving pharma, biotech, and healthcare investors with strategy, M&A due diligence, and operational advisory.
• PharmaVentures: Specialist transaction advisory firm focused exclusively on pharma, biotech, and medtech M&A and licensing. Comparable boutique competitor to InterPharmaLink in size and specialist healthcare transaction advisory.
• Charles River Associates: Global consulting firm offering economic and financial expertise including a dedicated Life Sciences practice serving pharma and biotech on strategy, M&A, and litigation. Comparable to InterPharmaLink in delivering transaction and business advisory to healthcare clients.
• Alacrita Life Science Consulting: Boutique life sciences consulting firm providing M&A, commercial, and operational advisory to pharma and biotech clients. Most closely comparable in size, specialty, and service scope to InterPharmaLink's healthcare advisory model.

Broad incumbents

• Boston Consulting Group (Healthcare): Global strategy consulting firm with a strong Healthcare practice serving pharma, biotech, and healthcare investors. Overlaps with InterPharmaLink on M&A, operational improvement, and corporate development advisory for healthcare clients.
• McKinsey & Company (Pharma & Medical Products): Global strategy consulting firm with a major Pharma & Medical Products practice serving the same enterprise healthcare clients as InterPharmaLink on M&A, operations, and corporate strategy. A much larger incumbent competing for overlapping mandates.
• Bain & Company (Healthcare): Global strategy consulting firm with a leading healthcare practice supporting pharma, biotech, and PE healthcare deals. Directly competes with InterPharmaLink on healthcare M&A diligence and value creation work, with broader sector coverage and larger team.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/interpharmalink-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles28 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InterPharmaLink